Detalhe da pesquisa
1.
LKB1: Can We Target an Hidden Target? Focus on NSCLC.
Front Oncol
; 12: 889826, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35646638
2.
NSCLC Cells Resistance to PI3K/mTOR Inhibitors Is Mediated by Delta-6 Fatty Acid Desaturase (FADS2).
Cells
; 11(23)2022 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36496978
3.
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
J Exp Clin Cancer Res
; 40(1): 286, 2021 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34507591
4.
LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments.
J Thorac Oncol
; 16(8): 1298-1311, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33887464
5.
Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines.
Am J Cancer Res
; 10(12): 4488-4497, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33415013
6.
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.
Front Oncol
; 10: 532292, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33194590
7.
Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation.
Cells
; 9(8)2020 07 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32718002
8.
LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors.
J Thorac Oncol
; 15(3): 360-370, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31634668
9.
KRAS Targeting and Resistance: Anticipating the Expectable.
J Thorac Oncol
; 16(8): 1239-1241, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34304850